Regeneron's Bispecific Antibodies Show Encouraging Anti Tumor Activity

  • Regeneron Pharmaceuticals Inc REGN announced early data for ubamatamab in recurrent ovarian cancer and REGN5093 in MET-altered advanced non-small cell lung cancer (NSCLC).
  • Within 42 patients who received full doses of ubamatamab, a 14% (6 of 42 patients) overall response rate (ORR) was achieved across dose levels. 
  • The ORR increased to 21% in those without visceral metastases and 31% in those with high MUC16-expressing tumors. 
  • Across dose levels, the disease control rate was 57%, and the median duration of response was 12 months.
  • Preliminary first-in-human results for REGN5093 were also published in an ESMO scientific abstract, with updated data and additional response rates.
  • Among 36 patients with MET-altered advanced NSCLC who received the highest dose tested to date, 6 experienced a partial response, with 5 of these responses occurring in patients who had received prior anti-PD-1 treatment. 
  • No dose-limiting toxicities or treatment-related deaths have been observed as of the data cutoff. 
  • Price Action: REGN shares closed higher by 2.18% at $724.32 on Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLarge CapNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!